Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning

Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning: A Multi-Center Cohort Study

This study aims to characterize the relationship between plasma diquat concentrations and organ damage risk.

Study Overview

• Status: Active, not recruiting
• Conditions: Diquat Poisoning; Toxic Encephalopathy
• Intervention / Treatment: Procedure: extracorporeal treatment

• Study Type: Observational
• Enrollment (Actual): 193

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210008
      • Nanjing Drum Tower Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with the history of acute diquat poisoning

Description

Inclusion criteria:

1. history of oral exposure to diquat solution reported by patient or proxy;
2. a specimen for the diquat plasma concentration collected immediately upon admission;
3. documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.

Exclusion criteria:

1. they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
2. diquat was not detected in specimens, or plasma concentration data were unavailable;
3. patients with an exposure time (time from exposure to emergency department presentation) longer than 48 hours;
4. data on organ damage were not unavailable;
5. combined with other central nervous system injuries other than toxic encephalopathy.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Survival outcome	28 days within the index date of presentation at emergency department

Collaborators and Investigators

• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2022
• Primary Completion (Actual): September 30, 2024
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: January 23, 2025
• First Submitted That Met QC Criteria: January 23, 2025
• First Posted (Actual): January 29, 2025

Study Record Updates

• Last Update Posted (Actual): December 5, 2025
• Last Update Submitted That Met QC Criteria: November 27, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Chemically-Induced Disorders; Poisoning; Neurotoxicity Syndromes; Therapeutics; Surgical Procedures, Operative; Respiratory Therapy; Extracorporeal Circulation; Extracorporeal Membrane Oxygenation
• Other Study ID Numbers: 2025-1047-02

Drug and device information, study documents

• product manufactured in and exported from the U.S.: No